Faculdade de Motricidade Humana da Universidade de Lisboa
Cruz Quebrada, Lisbon District, 1495-751, Portugal
NCT Number: NCT05184361
One of the major challenges for treating obesity is to maintain a weight reduced state on the long term due to the high rate of weight regain. Therefore, the aim of this study is to evaluate the effects of an intermittent versus a continuous energy restriction in body composition (body weight, fat mass and fat-free mass) and metabolic adaptation, in women with obesity.
Looking for future studies?
Notify Me20 year–45 year
Female
Interventional
Not applicable
Cruz Quebrada, Lisbon District, 1495-751, Portugal
Literature is full of lifestyle interventions aimed for weight loss (WL) in several populations. However, one of the major challenges for treating obesity is WL maintenance on the long term due to the high rate of weight regain.
The reduction of the resting metabolic rate (RMR) is one of the identified aspects regarding compensatory metabolic alterations. After a WL intervention, decreases in RMR are mainly explained by the loss of fat-mass (FM) and fat-free mass (FFM). However, some authors showed that these reductions tend to be higher than predicted (explained by FM and FFM loss), a phenomenon called "metabolic adaptation" (MA). MA has been studied as a possible barrier to WL, WL maintenance and may contribute to weight regain. However, its relevance on long-term WM has been recently questioned. It is known that in order to lose weight, a negative energy balance (EB) must be achieved, meaning when EE surpasses the energy intake (EI). However, this negative EB may be achieved through several strategies, by changing the EI (energy restriction (ER)) and/or EE (increasing physical activity).
Regarding EI strategies, continuous energy restriction (CER) is the most common nutritional strategy for WL, consisting in a daily energy restriction according to one's specific needs. However, some concern has been pointed out regarding this widely used strategy, once it evolves several behavioural, metabolic and endocrine responses that may contribute to therapeutic adherence, undermining WL and its maintenance. On the other hand, intermittent energy restriction (IER) has been recently suggested as an alternative to CER. IER consists in interspersing periods of ER with periods of neutral EB, called "refeed" or "diet breaks" during the WL phase. Energy restriction is followed by several adaptive responses, namely endocrine, including thyroid, appetite regulation and steroid hormones, influencing the energy expenditure (EE), body composition and satiety. Therefore, understanding how hormones may influence RMR and as a consequence, AT, it´s crucial to a better understanding.
According to the literature, compensatory metabolic responses following ER and WL can be reversed following a 7-to-14-day period of energy balance post-weight loss. Therefore, considering that the length of the nutritional intervention for WL may benefit a reduction, we consider relevant to study other ER designs/patterns, namely 2 weeks in ER interspersed with 1 week in EB, comparing to a CER. Taking into account this therapeutic as a potential opportunity for the obesity's treatment, this paper describes the protocol for a randomized controlled trial (RCT), which targets to evaluate the effects of an IER (alternating 2 weeks of ER with 1 in neutral EB), comparing to a CER. This trial aims: a) to compare the effects of a IER vs CER strategy on body composition variables (body weight, fat mass and fat-free mass) and in metabolic adaptation and, b) to understand if participants will be able to maintain a reduced weight state after 12 months (successful weight-loss maintenance), in both groups.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Both groups will be accompanied by a registered dietitian in order to provide an individual and personalized diet plan that will suppress the respective daily requirements for each phase. Macronutrient distribution will be the following: 35% protein, 35% carbohydrate and 30% fat.
Daily energy requirements (DER) will be calculated by multiplying measured RMR (through indirect calorimetry) by physical activity level (PAL), assessed by accelerometry.
In order to achieve a neutral EB, 100% of their daily energy requirements (DER) will be prescribed for each participant. For both groups, an energy restriction of 33% of one's DER will be created. The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.
The IER group will alternate between 2-weeks in energy restriction (67% DER) and 1-week in neutral EB (100% DER), in a total of 23-weeks.
A dietary plan comprising 67% of DER will be prescribed to the CER group. Participants will be asked to follow this plan in a total of 16-weeks, without interruptions.
Time frame: 24 months
To estimate total fat mass (FM), dual energy X-ray absorptiometry (Hologic Explorer-W, Waltham, USA) will be used. A whole-body scan will be performed and the attenuation of X-rays pulsed between 70 and 140 kV synchronously with the line frequency for each pixel of the scanned image will be measured.
Time frame: 24 months
AT will be assessed as: AT (kcal/d) = (pREE at the end of the intervention - mREE at the end of the intervention) - (pREE baseline - mREE baseline)
Time frame: 24 months
Weight will be determined using a digital scale, with 0,1 kg interval (Seca, Hamburg, Germany).
Time frame: Baseline
Height will be determined using a stadiometer Seca 704 s, with 0,1 cm intervals (Seca, Hamburg, Germany)
Time frame: 24 months
BMI will be calculated using the formula [weight (kg)/height2(m2)]
Time frame: 24 months
To estimate fat-free mass (FFM), dual energy X-ray absorptiometry (Hologic Explorer-W, Waltham, USA) will be used. A whole-body scan will be performed and the attenuation of X-rays pulsed between 70 and 140 kV synchronously with the line frequency for each pixel of the scanned image will be measured.
Time frame: 24 months
REE will be determined using indirect calorimetry COSMED Fitmate device (Cosmed, Rome, Italy) will be used to measure breath-by-breath oxygen consumption (V̇O2 ) and carbon dioxide production (V̇CO2) using a facial mask.
Time frame: 24 months
The EB will be calculated as: EB (kcal/d) = 1.0 * (ΔFMM/Δt) + 9.5 * (ΔFM/Δt). ΔFM and ΔFFM represent the change in grams of FM and FFM from the beginning to end of the intervention and Δt is the time length of the intervention in days.
Time frame: 24 months
The amount of activity assessed by the Actigraph accelerometer will be expressed as minutes per day spent in different intensities. The cutoff values used to define the intensity of PA and therefore to quantify the mean time in each intensity (sedentary, light, moderate or vigorous) will be: sedentary: < 100 counts·min-1; light: 100-2019 counts·min-1; moderate: 2020-5998 counts·min-1 (corresponding to 3-5.9 METs); vigorous: ≥ 5999 counts·min-1 (corresponding to ≥6 METs). A valid day will be defined as having 600 or more minutes (≥10h) of monitor wear during waking hours.
Time frame: 24 months
TDEE will be assessed by the Actigraph accelerometer using the Crouter et al equations.
Time frame: 24 months
PAEE will be calculated as total energy expenditure (TEE) minus (0.1*TEE + REE), assuming the thermic effect of food represents 10% of TEE, and REE represents Resting energy expenditure.
Time frame: 24 months
Free T3 and free T4 will be run by immunoassay with chemiluminescent detection (Advia Centaur, Siemens).
Time frame: 24 months
Blood insulin levels assessment will be performed in an automated analyser with chemiluminescent detection [Advia Centaur, Siemens].
Time frame: 24 months
Serum levels of leptin will be measured by enzyme immunoassay [ELISA].
Time frame: 24 months
Blood levels of cortisol will be determined by immunoassay with chemiluminescence detection [Advia Centaur, Siemens].
Universidade do Porto
Other
Acronym: BREAK
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00687115
Body Weight, Body Weight Changes
Phoenix, Arizona, United States
View Trial DetailsNCT05540314
Body Weight, Body Weight Changes
Dallas, Texas, United States
View Trial DetailsNCT01682317
Body Weight, Body Weight Changes
Knoxville, Tennessee, United States
View Trial DetailsNCT06501001
Behavior, Body Weight
Toledo, Spain
View Trial Details